We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Income investors love to target Dividend Aristocrats, companies that have increased their dividend payouts for a minimum of 25 consecutive years.
However, a step above is the elite Dividend Kings group, companies with at least 50 consecutive years of increased dividend payouts.
Clearly, companies in the Dividend King club carry well-established and successful business operations, displayed by their commendable commitment to shareholders over decades of increased payouts.
And several of them have outperformed the S&P 500 by a fair margin in 2022, including AbbVie (ABBV - Free Report) , Sysco Corp. (SYY - Free Report) , and Johnson & Johnson (JNJ - Free Report) . This is shown in the chart below.
Image Source: Zacks Investment Research
Let’s take a deeper dive into each one for those interested in building up a cash pile.
Johnson & Johnson
Headquartered in New Jersey, Johnson & Johnson is an American multinational corporation that develops medical devices, pharmaceuticals, and consumer packaged goods.
JNJ’s annual dividend yield comes in at a solid 2.7%, notably higher than its Zacks Medical sector average.
Further, the company carries a sustainable 45% payout ratio paired with a 6% five-year annualized dividend growth rate.
Image Source: Zacks Investment Research
Johnson & Johnson’s earnings streak is more than impressive; the company has exceeded the Zacks Consensus EPS Estimate in each quarter dating back to 2012.
Just in its latest print, JNJ registered a 2.4% EPS beat paired with a 2.2% sales surprise. Below is a chart illustrating the company’s revenue on a quarterly basis.
Image Source: Zacks Investment Research
Sysco Corp.
Sysco markets and distributes a range of food and related products primarily to the food service or food-away-from-home industry.
SYY’s 2.4% annual dividend yield is a few ticks below its Zacks Consumer Staples sector average of 2.8%. Still, the company’s 8.3% five-year annualized dividend growth rate helps to pick up the slack by a fair margin.
Image Source: Zacks Investment Research
It’s hard to ignore SYY’s growth profile; earnings are forecasted to climb more than 25% in its current fiscal year (FY23) and a further 12.5% in FY24.
The projected earnings growth comes on top of forecasted Y/Y revenue upticks of 11.3% and 4.3% for FY22 and FY23, respectively.
Image Source: Zacks Investment Research
SYY shares trade at a 19.4X forward earnings multiple, nicely beneath its 21.7X five-year median and a fraction of 2021 highs of 65.4X.
The company sports a Style Score of an A for Value.
Image Source: Zacks Investment Research
AbbVie
AbbVie, a global research-based biopharmaceutical company that delivers innovative medicines, became a top pharma company following its acquisition of Botox maker Allergan in a cash-and-stock deal for $63 billion in May 2020.
ABBV’s annual dividend yield comes in at a steep 3.9%, paired with an impressive 14% five-year annualized dividend growth rate. The company pays out 41% of its earnings.
Image Source: Zacks Investment Research
Shares trade at a 10.4X forward earnings multiple, above the 9.5X five-year median but representing a 53% discount relative to its Zacks Medical sector.
The company carries a Value Style Score of a B.
Image Source: Zacks Investment Research
Bottom Line
Targeting dividend-paying stocks is an excellent strategy that investors can deploy.
Dividends soften the blow from drawdowns in other positions, provide more than one way to reap a return from an investment, and allow maximum returns through dividend reinvestment.
And all three stocks above – AbbVie (ABBV - Free Report) , Sysco Corp. (SYY - Free Report) , and Johnson & Johnson (JNJ - Free Report) – are Dividend Kings, upping their dividend payouts for a minimum of 50 consecutive years.
For those seeking a reliable income stream, all three deserve serious consideration.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
3 Dividend Kings Crushing the S&P 500 in 2022
Income investors love to target Dividend Aristocrats, companies that have increased their dividend payouts for a minimum of 25 consecutive years.
However, a step above is the elite Dividend Kings group, companies with at least 50 consecutive years of increased dividend payouts.
Clearly, companies in the Dividend King club carry well-established and successful business operations, displayed by their commendable commitment to shareholders over decades of increased payouts.
And several of them have outperformed the S&P 500 by a fair margin in 2022, including AbbVie (ABBV - Free Report) , Sysco Corp. (SYY - Free Report) , and Johnson & Johnson (JNJ - Free Report) . This is shown in the chart below.
Image Source: Zacks Investment Research
Let’s take a deeper dive into each one for those interested in building up a cash pile.
Johnson & Johnson
Headquartered in New Jersey, Johnson & Johnson is an American multinational corporation that develops medical devices, pharmaceuticals, and consumer packaged goods.
JNJ’s annual dividend yield comes in at a solid 2.7%, notably higher than its Zacks Medical sector average.
Further, the company carries a sustainable 45% payout ratio paired with a 6% five-year annualized dividend growth rate.
Image Source: Zacks Investment Research
Johnson & Johnson’s earnings streak is more than impressive; the company has exceeded the Zacks Consensus EPS Estimate in each quarter dating back to 2012.
Just in its latest print, JNJ registered a 2.4% EPS beat paired with a 2.2% sales surprise. Below is a chart illustrating the company’s revenue on a quarterly basis.
Image Source: Zacks Investment Research
Sysco Corp.
Sysco markets and distributes a range of food and related products primarily to the food service or food-away-from-home industry.
SYY’s 2.4% annual dividend yield is a few ticks below its Zacks Consumer Staples sector average of 2.8%. Still, the company’s 8.3% five-year annualized dividend growth rate helps to pick up the slack by a fair margin.
Image Source: Zacks Investment Research
It’s hard to ignore SYY’s growth profile; earnings are forecasted to climb more than 25% in its current fiscal year (FY23) and a further 12.5% in FY24.
The projected earnings growth comes on top of forecasted Y/Y revenue upticks of 11.3% and 4.3% for FY22 and FY23, respectively.
Image Source: Zacks Investment Research
SYY shares trade at a 19.4X forward earnings multiple, nicely beneath its 21.7X five-year median and a fraction of 2021 highs of 65.4X.
The company sports a Style Score of an A for Value.
Image Source: Zacks Investment Research
AbbVie
AbbVie, a global research-based biopharmaceutical company that delivers innovative medicines, became a top pharma company following its acquisition of Botox maker Allergan in a cash-and-stock deal for $63 billion in May 2020.
ABBV’s annual dividend yield comes in at a steep 3.9%, paired with an impressive 14% five-year annualized dividend growth rate. The company pays out 41% of its earnings.
Image Source: Zacks Investment Research
Shares trade at a 10.4X forward earnings multiple, above the 9.5X five-year median but representing a 53% discount relative to its Zacks Medical sector.
The company carries a Value Style Score of a B.
Image Source: Zacks Investment Research
Bottom Line
Targeting dividend-paying stocks is an excellent strategy that investors can deploy.
Dividends soften the blow from drawdowns in other positions, provide more than one way to reap a return from an investment, and allow maximum returns through dividend reinvestment.
And all three stocks above – AbbVie (ABBV - Free Report) , Sysco Corp. (SYY - Free Report) , and Johnson & Johnson (JNJ - Free Report) – are Dividend Kings, upping their dividend payouts for a minimum of 50 consecutive years.
For those seeking a reliable income stream, all three deserve serious consideration.